Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trans-arterial chemoembolisation versus embolisation alone in non-resectable hepatocellular carcinoma
ISRCTN63349435Phase 3Completed
- Sponsor
- United States Department of Health and Human Services
- Start
- Oct 2003
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, open-label trial of cisplatin in hepatocellular carcinoma (HCC) and liver cancer (2 arms), sponsored by United States Department of Health and Human Services. Primary endpoints: Overall survival, Quality of life and 2 more. Started Oct 2003; status: completed.
02
Drugs
cisplatin
03
Conditions
hepatocellular carcinoma (HCC)liver cancer
Beyond the preview
Go deeper on ISRCTN63349435.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN63349435.